Placental growth factor at 24-28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trial.
Marta RicartErika BonacinaPablo Garcia-ManauMonica LópezSara CaamiñaÀngels VivesEva Lopez-QuesadaAnna MarotoLaura de MingoElena PintadoRoser Ferrer-CostaLourdes MartínAlicia Rodriguez-ZuritaEsperanza GarciaMar PallarolsLaia PratcoronaMireia TeixidorCarmen Orizales-LagoVanesa OcañaEsther Del BarcoElena CarrerasAnna SuyManel MendozaPublished in: Acta obstetricia et gynecologica Scandinavica (2024)
Discontinuation of aspirin treatment at 24-28 weeks in women with PlGF levels ≥100 pg/mL was non-inferior to continuing until 36 weeks for preventing preterm PE. However, these findings should be interpreted with caution, as they originate from a subanalysis of the StopPRE trial.
Keyphrases
- gestational age
- growth factor
- preterm birth
- low dose
- study protocol
- phase iii
- phase ii
- cardiovascular events
- antiplatelet therapy
- low birth weight
- early onset
- randomized controlled trial
- open label
- cardiovascular disease
- pregnancy outcomes
- pregnant women
- preterm infants
- acute coronary syndrome
- combination therapy
- anti inflammatory drugs
- replacement therapy
- placebo controlled